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Abstract
Background: Despite recent technical advances in the management of acute kidney injury (AKI), such as
continuous renal replacement therapy (CRRT), intensive care unit mortality is still high, at approximately 40 to 50%.
Although several factors have been reported to predict mortality in AKI patients, fluid overload (FO) during CRRT is
a well-known predictor of patient survival. However, FO has been mostly quantified as an arithmetical calculation
and determined on the basis of the physicians’ perception. Even though such quantification and assessment
provides an easy evaluation of a patient’s fluid status and is a simple method, it is not applicable unless a detailed
record of fluid monitoring is available. Furthermore, the method cannot differentiate excess water in individual
water compartments but can only reflect excess total body water. Bioimpedance analysis (BIA) has been used to
measure the nutritional component of body composition and is a promising tool for the measurement of volume
status. However, there has been no prospective interventional study for fluid balance among CRRT-treated AKI
patients using BIA. Therefore, we will investigate the usefulness of fluid management using the InBody S10
(InBody®, Seoul, Korea), a BIA tool, compared with that of generally used quantification methods.
Methods/design: This will be a multicenter, prospective, randomized controlled trial. A total of 244 patients
undergoing CRRT treatment will be enrolled and randomly assigned to receive either to InBody S10-guided
management or to fluid management based only on clinical information for 7 days. The primary outcome is to
compare the rate of euvolemic status 7 days after the initiation of CRRT, with a secondary outcome being to
compare the 28-, 60-, and 90-day mortality rates between the two groups.
Discussion: This will be the first clinical trial to investigate the effect of using BIA-guided fluid management to
achieve euvolemia in CRRT-treated AKI patients.
Trial registration: ClinicalTrials.gov, ID: NCT03330626. Registered on 6 November 2017.
Keywords: Fluid balance, Bioimpedance analysis (InBody S10 (InBody®) Seoul, Korea), Continuous renal replacement
therapy (CRRT)
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Background
Continuous renal replacement therapy (CRRT) has been
established to manage the excretion of toxins and the bal-
ance of electrolytes and fluids in critically ill patients with
acute kidney injury (AKI) [1–4]. Despite technical ad-
vances in the management of AKI over the past few years
[5, 6], intensive care unit (ICU) mortality is still high at
approximately 40 to 50% [7–10]. Although several factors
have been reported to predict mortality in AKI patients [7,
8], fluid overload (FO) at the initial time of CRRT is a
well-known predictor of patient survival [7, 11–16]. A few
recent studies have examined the effect of fluid accumula-
tion on mortality: Neyra et al. [14] showed that higher cu-
mulative fluid balance during 72 h of ICU admission was
independently associated with hospital mortality regard-
less of AKI or chronic kidney disease (CKD) presence; in
the Randomized Evaluation of Normal vs. Augmented
Level of Replacement Therapy (RENAL) study, a negative
mean daily fluid balance was consistently related to im-
proved clinical outcomes [15]; and Garzotto et al. [16] em-
phasized the association between the severity and speed of
fluid accumulation and ICU mortality.
However, FO has been mostly quantified as an arith-
metical calculation: the difference between the sum of
daily fluid intake and total output adjusted by body
weight and determined based on the physician’s percep-
tion. Even though such quantification and assessment is
an easy mechanism to evaluate a patient’s fluid status
and is a basic method, it is not applicable unless a de-
tailed record of the fluid monitoring is available, and it
cannot differentiate water excess in individual water
compartments; instead, the method can only reflect ex-
cess total body water (TBW) [17].
Bioimpedance analysis (BIA) has been used to measure
the nutritional part of body composition, such as fat
mass or fat-free mass (FFM), in diverse conditions [18,
19]. However, it has been used as a promising tool for
the measurement of volume status [20]. With the elec-
trical properties of body tissues, multifrequency-BIA
(MF-BIA) differentiates extracellular water (ECW) or
intracellular water (ICW) from TBW using different fre-
quencies: 0, 1, 5, 50, 100, 200, 500 or 1000 kHz [21, 22].
To date, several studies have demonstrated the accuracy
and clinical usefulness of MF-BIA in chronic
hemodialysis or peritoneal dialysis patients [23–27].
Moreover, in critically ill patients, MF-BIA has been use-
ful in assessing volume status [28] and net fluid removal
using CRRT to successfully reduce TBW, ECW, and
ICW [29]. Rhee et al. [17] investigated the effect of
MF-BIA-defined volume status on the mortality of crit-
ically ill patients with AKI; the authors demonstrated
that MF-BIA-defined excess volume parameters adjusted
for the square of the patient’s height (H2), such as TBW/
H2 and ICW/H2, were independently associated with
higher in-hospital mortality in male patients with AKI
undergoing CRRT. However, there has been no pro-
spective interventional study for fluid balance among
CRRT-treated AKI patients using the abovementioned
BIA. Therefore, in this study, we will investigate the use-
fulness of fluid management using InBody S10 (InBody®,




BIA-guided fluid management will reach an euvolemic
status in patients who are treated with CRRT better than
fluid management guided by a generally used quantifica-
tion method, which is calculated by the difference be-
tween the sum of daily fluid intake and total output
adjusted by body weight and determined based on the
physician’s perception. Moreover, the patients who
achieve a euvolemic status 7 days after the initiation of
CRRT will have better clinical outcomes based upon 28-,
60-, and 90-day mortality than those of patients who are
still in a higher-volume status at the same time.
Study design
This will be a multicenter, prospective, parallel-group,
open-label, randomized controlled trial. It is an
investigator-initiated clinical trial. We have followed
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Statement which
defines standard protocol items for clinical trials
(Additional file 1). The overall study algorithm is
depicted in Fig. 1 and the SPIRIT and study schedule
are given in Fig. 2. After enrollment, InBody S10
(InBody®, Seoul, Korea) will be used to measure fluid
status at 0, 1, 2, and 7 days after the initiation of the
CRRT in InBody S10-based fluid management group,
but at 0 and 7 days in fluid management guided by a
generally used quantification method. Physicians will
not know the results of the InBody S10 measurement.
Instead, another investigator will measure the InBody S10
and record the results. In the treatment group, the fluid
monitoring will be managed according to Table 1, while
the fluid balancing of the control group will be conducted
based on the clinical information obtained by the phys-
ician, such as body weight, hemodynamic stability and
daily intake and output. Clinical information including
hemodynamic monitoring and laboratory data will be col-
lected on the same days, and we will investigate the 28-,
60-, and 90-day survival status.
Study participants and measurements
All patients will be selected from among patients who
must be treated with CRRT in four tertiary hospitals in
Korea (Seoul National University Bundang Hospital,
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Fig. 1 The overall study algorithm. After enrollment, InBody S10 (InBody®, Seoul, Korea) will be used to measure fluid status at 0, 1, 2, and 7 days
after the initiation of the continuous renal replacement therapy (CRRT) in InBody S10-based fluid management group, but at 0 and 7 days in fluid
management guided by a generally used quantification method. Abbreviations: AKI acute kidney injury, CRRT continuous renal replacement
therapy, D0 the day of CRRT initiation, D1, 2 and 7 1, 2 and 7 days from the day of CRRT initiation, respectively
Fig. 2 Schedule of enrollment, interventions, and assessments according to the Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guideline. Abbreviations: TBW total body water, ICW intracellular water, ECW extracellular water, TBW/H2 total body water/height2
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Seoul National University Hospital, Seoul National Uni-
versity Boramae Medical Center, and Ewha Womans
University Mokdong Hospital). Patients aged over 18
years who require CRRT for AKI will be screened for
study participation according to the inclusion and exclu-
sion criteria presented in Table 2.
Randomization
A research coordinator will perform the randomization. A
list of random numbers will be generated by an independent
statistician. Eligible participants will be randomly assigned
1:1 to either the control group (fluid management based on
the clinical information alone) or the treatment group
(InBody S10 (InBody®, Seoul, Korea)-guided fluid manage-
ment alone). Randomization will be stratified based on the
institution and will utilize a randomized block design.
Outcome measures
The primary outcome is to compare the rate of euvole-
mic status at 7 days from the CRRT start. The euvolemic
status will be considered different when TBW/H2 be-
tween the day of CRRT initiation (D0) and 7 days from
the day of CRRT initiation (D7) is less than − 2.1 or
TBW/H2 at D7 is less than 13 L/m2. According to
Rhee’s recent study, the group reaching TBW/H2 < 13
L/m2 had a significantly enhanced survival rate com-
pared with that of the group that could not reach
TBW/H2 < 13 L/m2 [17]. Moreover, our further study
has revealed that the survival rate was significantly
increased when the difference in TBW/H2 between
CRRT initiation and at 7 days from CRRT start
(TBW/H2 at 7days – TBW/H
2
at CRRT initiation) was less
than − 2.1 L/m2, even though it was not sufficient to
reach TBW/H2 < 13 L/m2 (data not shown). Therefore,
we will also consider the euvolemia as TBW/H2 at
7days – TBW/H
2
at CRRT initiation < − 2.1 L/m
2 in this
study. The secondary outcome is to investigate the
28-, 60-, and 90-day mortality rates in the control
and treatment groups and to compare the mortality
rates between the groups that reach euvolemic status
or not for sub-analysis.
Assessment of the fluid status
For participants in the control group, clinical informa-
tion obtained by the physician is the standard of judg-
ment. However, the participants will be measured by
InBody S10 (InBody®) at D0 and D7, and the results will
Table 1 The guideline of fluid management for treatment group
TBW/H2 at D0, D1, D2 Target fluid removal amount (L/H2/day)







Fluid removal will be determined based on the TBW/H2 for 3 days (D0, D1, D2). However, fluid will be removed by 1 L/day if calculated fluid removal from the
TBW/H2 is over 1 L/day
Table 2 Inclusion and exclusion criteria
Inclusion criteria
Patients will be eligible for inclusion in the study if all the following
criteria are met:
1. The treating clinician believes that the patient requires
continuous renal replacement therapy for acute kidney injury
2. The treating clinicians anticipate treating the patient with
continuous renal replacement therapy for at least 72 h
3. Informed consent has been obtained
4. The patient fulfills one of the following clinical criteria for
initiating continuous renal replacement therapy:
Urine output < 100mL/6 h that has been unresponsive
to fluid resuscitation measures
K+ > 6.5 mmol/L
pH < 7.2
Urea > 25 mmol/L
Clinically significant organ edema in the setting of acute
kidney injury
5. Patients who are over 5% of fluid overload or their total body
water/height2 ≥ 13 L/m2
Exclusion criteria
Patients will be excluded from the study if, in the opinion or knowledge
of the responsible clinician any of the following criteria are present:
1. Patient age is < 18 years
2. Death is imminent (< 24 h)
3. There is a strong likelihood that the study treatment will not be
continued in accordance with the study protocol.
4. The patient has been treated with continuous renal replacement
therapy or other dialysis previously during the same hospital
admission.
5. The patient has been on maintenance dialysis prior to the current
hospitalization.
6. Any other major illness that, in the investigator’s judgment, will
substantially increase the risk associated with the subject’s
participation in this study.
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be recorded. Clinical information will be composed of
four items: body weight in the morning; hemodynamic
stability; absence of symptoms and signs of hypervole-
mia (dyspnea, edema, and crackle) or hypovolemia
(dizziness and orthostatic hypotension); and daily intake
and output. For participants in the treatment group,
InBody S10 (InBody®) will also be measured at 9:00 a.m.
on D0, D1, D2, and D7. Table 1 shows the guideline of
fluid management for the treatment group. However,
both the physicians and participants will be blinded to
the results of InBody S10 (InBody®) analysis.
InBody S10 (InBody®) is a medical device that has been
approved by the US Food and Drug Administration as
an impedance body-fat analyzer. The device provides the
following parameters: TBW, ICW, ECW, segmental
water values, ECW ratio (ECW/TBW), FFM, soft lean
mass (SLM), segmental lean mass, body fat mass (BFM),
percentage body fat (PBF), and TBW/FFM.
The BIA method calculates body composition using the
resistance value (impedance) that appears due to the dif-
ference in electrical conductivity according to the bio-
logical characteristics of each tissue. Electrical
conductivity is proportional to the amount of water and
electrolytes, and the water content of fat tissue is relatively
smaller than that of other tissues, which leads to a de-
crease in electrical conductivity when the fat content in-
creases. Among the components of the body, body water
is the component that passes an electrical current, so the
volume of water in the body can be obtained by measuring
the resistance value obtained from body water [21].
Clinical and laboratory evaluations
Physical examination, comorbidity and medication will be
reviewed. Laboratory evaluations, including complete
blood cell counts (CBC), electrolytes, creatinine, protein,
albumin, calcium, phosphorous, total cholesterol, trigly-
ceride, low-density lipoprotein cholesterol, high-sensitivity
C-reactive protein (hs-CRP), and N-terminal prohormone
of brain natriuretic peptide (NT-proBNP) will also be per-
formed in the morning in the intensive care unit.
Safety issues
The InBody S10 (InBody®) method approved by the US
Food and Drug Administration has been used in clinical
practice. Applying weak alternating currents into the
body is known to not be harmful.
Sample size calculations
No previous report has evaluated the effect of InBody
S10 (InBody®)-guided fluid management on
CRRT-treated patients. We will randomly divide the en-
rolled participants equally into two groups. Assuming a
19% difference in the rate of achieving euvolemic status
between the two groups with 0.8 of power, two-sided,
and 0.05 of alpha, 97 participants will be allocated in
each group. However, 122 participants will be required
to enroll in each group due to a 20% withdrawal rate.
Statistical analyses
The statistical analyses will be conducted both on a
per-protocol (PP) and an intention-to treat (ITT) basis.
For PP analysis, all participants who complete the study
will be included to evaluate the primary and secondary
outcomes. For the ITT analysis, all participants who are
enrolled and randomized to one of the two groups and
who complete the first visit will be included. Basic statis-
tics will be reported in terms of the mean ± SD for con-
tinuous variables, or as percentages for categorical
variables. Differences between groups will be analyzed
using Student’s t test for continuous variables and the χ2
test or Fisher’s exact test for categorical variables. The
primary outcome will be compared with Student’s t test.
An analysis of covariance (ANCOVA) will be used to
analyze the primary outcome as the secondary analysis
to adjust the baseline value. Multivariate Cox propor-
tional hazard regression models will be used to analyze
the time to mortality. Although the institutions are
mainly located in large cities, thereby limiting the likeli-
hood of any important cluster effect, we will be sure to
accommodate possible clustering in our models and ana-
lysis as required. A value of P < 0.05 will be considered
statistically significant. All analyses will be performed
using SPSS Statistics software (v21.0; IBM Corporation,
Armonk, NY, USA).
Ethics approval
The study will be performed in accordance with the
Declaration of Helsinki, as amended by the 59th World
Medical Association General Assembly in 2008. All the
participants will provide signed, informed, written con-
sent, stating that participation is voluntary and can be
withdrawn at any time. Approval for the study has been
obtained from the Institutional Review Board of Seoul Na-
tional University Bundang Hospital (B-1702/383–003),
Seoul National University Hospital (J-1705-080-855),
Seoul National University Boramae Medical Center
(20,170,516/20–2017-2/062), Ewha Womans University
Mokdong Hospital (EUMC 2017–05–049-008) (Ethical
Approval Document). The trial protocol has been regis-
tered at https://clinicaltrials.gov/ct2/show/NCT03330626
(NCT03330626). Moreover, this research was supported
by a grant from the Korea Health Technology R&D
Project through the Korea Health Industry Develop-
ment Institute (KHIDI), funded by the Ministry of
Health and Welfare, Republic of Korea (grant num-
ber: HI17C1827) (Funding Documentation).
Oh et al. Trials          (2018) 19:681 Page 5 of 7
Discussion
CRRT is a generally used tool to manage fluid balance
among the critically ill patients with AKI when they have
medically refractory overhydration [1–4]. Moreover, some
recent studies have emphasized the effects of cumulative
fluid balance on mortality among CRRT-treated AKI pa-
tients [14–16]. However, FO has been mostly quantified as
an arithmetical calculation using the following equation:
(The sum of daily fluid intake − total output) / (Body
weight). This condition has been determined based on the
physician’s perception. However, it is not applicable unless
a detailed record of fluid monitoring is available, and it
cannot differentiate water excess in individual water com-
partments [17], although such quantification and assess-
ment represents an easy and basic method to evaluate a
patient’s fluid status.
InBody S10 (InBody®) is a medical device using
MF-BIA and has been approved by the US Food and
Drug Administration as an impedance body-fat analyzer
that also provides analysis of individual water compart-
ments, such as TBW, ICW, ECW, segmental water
values, and ECW ratio (ECW/TBW).
MF-BIA has proven to be useful for assessing volume
status in critically ill patients [28, 29] and Rhee et al. [17]
showed the effect of MF-BIA-defined volume status on the
mortality of critically ill patients with AKI using InBody
S20 (InBody®). As there has not yet been a prospective
interventional study of fluid balance among CRRT-treated
AKI patients using the abovementioned BIA, we will in-
vestigate the usefulness of fluid management using the
BIA device InBody S10 (InBody®) and compare the results
with a generally used quantification method.
To our knowledge, this will be the first multicenter,
prospective, randomized controlled trial to assess
whether InBody S10-guided volume management is bet-
ter able to reach a euvolemic status at 7 days after the
initiation of CRRT than the quantitation method for
volume management is. The endpoint of the VENUS
(VolumE maNagement Under body composition moni-
toring in critically ill patientS on CRRT) study may be of
the utmost importance to healthcare providers.
So far, there is no definite index for determining euvo-
lemic status. Instead, most physicians determine their
patients’ volume status based on clinical information,
such as intake and output, chest radiographic examin-
ation, and physical examination. Therefore, the fluid bal-
ance of patients may be managed differently based on
the physicians’ opinions, even with the same patients.
The abovementioned study by Rhee et al. [17] suggested
that TBW/H2 and ICW/H2 were independently associ-
ated with higher in-hospital mortality in male patients
with AKI undergoing CRRT, and the group reaching
TBW/H2 < 13 L/m2, which was 13% of total enrolled pa-
tients, had a significantly increased level of survival
compared to that of other patients. Thus, we will define
the euvolemia as the status of TBW/H2 < 13 L/m2. In
addition, our study of fluid removal has revealed that the
difference in TBW/H2 between CRRT initiation and at
day 7 of CRRT,[(BW/H2 at 7days – TBW/H
2
at CRRT initi-
ation), especially when it was greater than − 2.1 L/m
2, was
significantly associated with an increased mortality rate,
even though it did not reach TBW/H2 < 13 L/m2 (data
not shown). Therefore, we will also consider another
measure of euvolemia in this study, namely TBW/H2 at
7days – TBW/H
2
at CRRT initiation < − 2.1 L/m
2.
There is a chance that patients within the same institu-
tion will be correlated more closely than patients at differ-
ent institutions will. To avoid this issue, we will investigate
for the possible clustering of patients at the recruitment
institution level and will accommodate such clustering in
our models and analysis as required. We have also conser-
vatively calculated the sample size, assuming a high
drop-out rate, to overcome this potential problem.
There are a few limitations in this study. First, this
study will be investigated in Korean Tertiary Hospitals,
which means that the results will require cautious inter-
pretation concerning ethnicity. Second, we have defined
euvolemia arbitrarily, although this definition was based
on recent data and upon our own study. However, this
study is the first study, to the best our knowledge, to de-
termine guidelines for the fluid balance in CRRT-treated
critically ill AKI patients using a prospective randomized
controlled trial. We expect that the endpoint of the
VENUS study will provide the utmost information to
healthcare providers.
In summary, the VENUS study is the first prospective,
randomized controlled trial to evaluate the clinical useful-
ness of InBody S10-guided fluid management in
CRRT-treated critically ill AKI patients. The aim of this
study is to identify more objective guidelines to manage
volume status in CRRT-treated, critically ill AKI patients.
Trial status
This trial is ongoing. Participants are currently being
recruited.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
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